Lund, Sweden, 2011-11-04 09:28 CET (GLOBE NEWSWIRE) --
BONENAVI was in major focus at the annual meetings of JSNM2011 (Japanese Society of Nuclear Medicine) and JSNMT31 (Japanese Society of Nuclear Medicine Technology) in Tsukuba, October 27-29. During the scientific program there were twenty-seven oral presentations made including BONENAVI, the Japanse version of EXINI bone™ developed in corporation with FUJIFILM Ri Pharma.
JSNM 2011 and JSNMT 2011 was a success for EXINI. During two intense days 27 oral presentations were made related to the work accomplished by the Company’s software.
Thomas Jonsson, Sales Director Asia and representative of EXINI in Tsukuba:
- "The response from the Japanese market that we receive right now is incredible. The doctors in Japan have acknowledged BONENAVI, the Japanese version of EXINI bone™, even faster than we would dare to hope. Through their accurate follow-up, they prove that BONENAVI contribute to an increased capacity and quality within nuclear medicine.
Selection of oral presentations made at JSNM2011:
Prognostic potential of bone scint CAD software in prostate cancer, Dr. Takahashi at Tokyo Medical University
"EOD (extent of disease) score and BSI have been shown to be useful in the prognosis of prostatic cancer. However, both methods are difficult to conduct and result differs between evaluators. We evaluated the correlation between EOD and the bone scint software BONENAVI from Exini Diagnostics AB.”
Conclusion: “There is a correlation between EOD and the automatically reported BSI. Automatically calculated BSI was shown to be useful in the prognosis of prostate cancer."
Evaluation of usefulness of BONENAVI, Dr. Uchiyama from Hokkaido University Hospital
In this study 28 cancer patients were evaluated focusing on the usefulness of the Normalization, Segmentation, Hotspots and ROI features of BONENAVI.
Conclusion: “Number of bone scints will increase when you can use BONENAVI as a quantification tool.”
Evaluation of segmentation in the bone scint CAD software BONENAVI, Dr. Yonishi of Fukui Prefecture Saiseikai Hospital
An important issue for a good quantification tool is the possibility for automatic segmentation of the skeletal. We evaluate the rate of segmentation errors with BONENAVI.
Conclusion: “Very few segmentation errors were found in clinical use of BONENAVI, less than 2% incorrect cases. The incorrect cases were mostly related to non-optimized placement of the patients in the camera.”
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt and currently has 13 employees. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com